Overview

G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: G-CSF may prevent or control neutropenia caused by first-line therapy in patients with metastatic colorectal cancer. PURPOSE: This phase II trial is studying how well G-CSF works in preventing neutropenia during first-line treatment with chemotherapy and bevacizumab in patients with metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Federation Francophone de Cancerologie Digestive

Treatments:

Bevacizumab
Calcium
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin